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Many types of cancer cells show a characteristic increase in glycolysis, which is called 34 
the “Warburg effect.” By screening plant extracts, we identified one that decreases 35 
cellular adenosine triphosphate (ATP) levels and suppresses proliferation of malignant 36 
melanoma B16F10 cells, but not of noncancerous MEF cells. We showed that its active 37 
ingredient is emodin, which showed strong antiproliferative effects on B16F10 cells both 38 
in vitro and in vivo. Moreover, we also found that emodin can function as a mitochondrial 39 
uncoupler. Consistently, three known mitochondrial uncouplers also displayed potent 40 
antiproliferative effects and preferential cellular ATP reduction in B16F10 cells, but not 41 
in MEF cells. These uncouplers provoked comparable mitochondrial uncoupling in both 42 
cell types, but they manifested dramatically different cellular effects. Namely in MEF 43 
cells, these uncouplers induced three to fivefold increases in glycolysis from the basal 44 
state, and this compensatory activation appeared to be responsible for the maintenance of 45 
cellular ATP levels. In contrast, B16F10 cells treated with the uncouplers showed less 46 
than a twofold enhancement of glycolysis, which was not sufficient to compensate for the 47 
decrease of ATP production. Together, these results raise the possibility that uncouplers 48 
could be effective therapeutic agents specifically for cancer cells with prominent 49 




















1 | INTRODUCTION 69 
      Even with the impressive advances in medical care over the last several decades, 70 
about one out of two Japanese suffers from cancer over their lifetime, and one third of 71 
Japanese die of cancer. One of the most prominent characteristics of cancer cells, 72 
regardless of type or stage, is their uncontrolled, aggressive proliferation. Such aggressive 73 
proliferation requires a vast amount of cellular energy in the form of 74 
adenosine triphosphate (ATP), as compared with noncancerous cells, as cell proliferation 75 
entails many energy‐consuming steps, for example, synthesis of proteins and RNAs 76 
(rRNA, mRNA and tRNA), DNA replication and cytokinesis (Buttgereit & Brand, 1995; 77 
Gibbons & Rowe, 1965; Summers & Gibbons, 1971). As a consequence, cancer cells 78 
should be sensitive to ATP depletion by various means. 79 
      It is well known that many types of cancer cells show a characteristic increase in 80 
glycolysis, even in aerobic conditions, a phenomenon is called “Warburg effect” 81 
(Warburg, 1956; Warburg, Posener, & Negelein, 1924). Thus, glycolysis has garnered 82 
considerable interest as a possible therapeutic target. From this point of view, 2‐deoxy‐83 
D‐glucose (2‐ DG), a nonmetabolizable glucose analogue that inhibits glycolytic 84 
hexokinase, had been assessed as an anticancer drug in clinical trials. Disappointingly, 85 
however, patients treated with 2‐DG showed severe side effects, so this drug is now under 86 
  
evaluation in combined therapies with other chemotherapeutic compounds (Dwarakanath 87 
& Jain, 2009; Mohanti et al., 1996; Singh et al., 2005; Vander Heiden, 2011).  88 
      Recent epidemiologic studies have shown that diabetic patients treated with 89 
metformin manifest lower incidence of various types of cancers, such as breast cancer, 90 
colorectal cancer, pancreatic cancer and lung cancer (Bodmer, Meier, Krahenbuhl, Jick, 91 
& Meier, 2010; Evans, Donnelly, Emslie‐ Smith, Alessi, & Morris, 2005; Vernieri et al., 92 
2016; Yin, Zhou, Gorak, & Quddus, 2013; Zhang et al., 2014). In 2000, it was reported 93 
that a target of metformin in cancer cells was mitochondrial respiratory chain complex Ⅰ 94 
(El‐Mir et al., 2000; Owen, Doran, & Halestrap, 2000), and this drug is now being tested 95 
in clinical trials for different types of cancers (Vernieri et al., 2016). In preclinical 96 
research, there are two types of compounds that are expected to be efficacious as new 97 
anticancer drugs, which also target the mitochondrial energy metabolism (Weinberg & 98 
Chandel, 2015). The first one, tigecycline, is an inhibitor of translation of electron 99 
transport chain (ETC) proteins, (Skrtić et al., 2011), and the second one is Gamitrinib 100 
which inhibits heat shock protein‐90 (HSP90) and tumor necrosis factor receptor‐101 
associated protein‐ 1 (TRAP‐1) ATPase. This inhibitor lead to a decrease of ATP 102 
production from oxidative phosphorylation (OXPHOS) (Chae et al., 2012).  103 
      Malignant melanoma has the dubious distinction of having one of the worst 104 
  
prognoses, because of its aggressive metastatic nature from early stages. Melanoma is 105 
responsible for over 75% of skin cancer death (Corrie, Hategan, Fife, & Parkinson, 2014), 106 
and its incidence is rapidly increasing (Siegel, Miller, & Jemal, 2018). The two‐year 107 
overall survival rate of malignant melanoma patients at stage Ⅳ is only 10.7% (Sandru, 108 
Voinea, Panaitescu, & Blidaru, 2014). Recently, some molecularly targeted therapies 109 
have achieved extensive attention as new melanoma treatments, like vemurafenib 110 
and nivolumab (Schadendorf et al., 2018). However, the treatments by vemurafenib, a 111 
specific inhibitor of BRAF V600E, have allowed responsive tumors to be resistant to this 112 
chemotherapy (Flaherty et al., 2010). On 2014, a PD‐1 blocking antibody drug, 113 
“nivolumab,” was approved as a new drug, but the objective response rate to treatment of 114 
metastatic melanoma without a BRAF mutation was not satisfying, 40% (Robert et al., 115 
2015). Thus, melanoma remains one of the most refractory neoplasms in spite of these 116 
energetic studies, and it is an urgent need to develop a more effective strategy for the 117 
treatment.  118 
      B16F10 cells, which were established from a mouse malignant melanoma (Fidler, 119 
1973), serve as a model to examine the efficacies of experimental drugs in vitro and in 120 
vivo. In this study, we evaluated compounds that reduce ATP levels in B16F10 cells and 121 
found a plant extract from rhizomes of Polygonum cuspidatum (RPC). This plant extract 122 
  
has long been administrated to human body as a component of a traditional medicine, and 123 
various types of pharmacological effects are known like treating cough, hepatitis, 124 
jaundice, arthralgia and skin burns. Although recent studies reported that this extract has 125 
antiviral, antimicrobial, anti‐inflammatory, neuroprotective and cardioprotective 126 
activities (Peng, Qin, Li, & Zhou, 2013; Zhang, Li, Kwok, Zhang, & Chan, 2013), 127 
there are no reports about the ATP reduction in cancer cells. Here, we show an active 128 
ingredient in RPC, emodin, manifests antiproliferative effects on B16F10 cells, and acts 129 
as a “mitochondrial uncoupler” following ATP down‐regulation. We thus propose 130 
mitochondrial uncoupling as a potential therapeutic strategy for cancer treatment, 131 
especially for cancers with enhanced energetic demands and reduced glycolytic 132 
reserves, like melanoma. 133 
 134 
2 | RESULTS 135 
2.1 | Plant extracts from rhizomes of Polygonum cuspidatum preferentially 136 
decreases cellular ATP levels in B16F10 cells but not MEFs 137 
      We compared growth rates and metabolic activities of two mouse cell lines, 138 
malignant melanoma B16F10 and mouse embryonic fibroblasts (MEF). Proliferation 139 
rates of B16F10 cells were much higher than those of MEF cells (Figure 1a). Assuming 140 
  
that highly proliferating cancer cells display enhanced energy metabolism, we compared 141 
several metabolic indicators between the two cell lines. The extracellular 142 
acidification rate (ECAR), which indicates the strength of glycolysis, was significantly 143 
higher in B16F10 cells than in MEF cells (Figure 1b); moreover, the ECAR in B16F10 144 
cells was also higher than in HeLa (derived from cervical cancer) and A549 cells (derived 145 
from lung cancer) (Figure S1a), consistent with the notion that B16F10 cells manifest a 146 
prominent Warburg effect. The oxygen consumption rate (OCR), which indicates the 147 
strength of mitochondrial respiration, was also much higher in B16F10 cells than in MEF, 148 
HeLa and A549 cells (Figure 1c, Figure S1b). The mitochondrial membrane potential was 149 
also much higher in B16F10 cells than in MEF cells (Figure 1d). These results imply that 150 
B16F10 cells rely on active energy metabolism through not only glycolysis but also 151 
mitochondrial respiration, which likely contribute to the aggressive proliferation of these 152 
cells. We also measured ATPase activities of whole cell lysates (Manno, 153 
Noguchi, Fukushi, Motohashi, & Kakizuka, 2010) and found that the rate of ATP 154 
hydrolysis of B16F10 cell extracts was about twice the rate in MEF cell extracts (Figure 155 
1e). These results were consistent with the notion that B16F10 cells produce and consume 156 
cellular ATP more actively than MEF cells. 157 
      On the assumption that some plant extracts used in Chinese medicine might 158 
  
reduce ATP levels in highly proliferating cells, we screened more than 1,000 plant 159 
extracts and found one (extract A) that was able to decrease cellular ATP levels in 160 
B16F10 cells, but not in MEF cells (Figure 1f). Extract A was derived from rhizomes of 161 
Polygonum cuspidatum (RPC). 162 
 163 
2.2 | Emodin is the principle active ingredient in the RPC extract 164 
      In order to identify active ingredients in the RPC extract, we carried out polarity‐165 
based fractionations (Figure 2a). For this purpose, we used the second lot (#2) of the RPC 166 
extract, which was prepared in a larger amount, although its activity was lower than the 167 
first lot (#1) (Figure 2b). First, we separated the extract into two fractions, water‐soluble 168 
(F1) and organic‐soluble (F2), by the Bligh–Dyer method. We treated B16F10 and MEF 169 
cells with each of the two fractions at 100 μg/ml for 6 hr and measured ATP levels of the 170 
cells. The results showed that the F2 fraction drastically decreased cellular ATP levels in 171 
B16F10 cells, and this effect was clearly much weaker in MEF cells (Figure 2b). Next, 172 
F2 was dissolved in 100% CHCl3, followed by solid phase extraction (SPE), and we 173 
separated it into three fractions, F2‐1 (eluted by 100% CHCl3), F2‐2 (eluted by 174 
CHCl3:MeOH = 4:1) and F2‐3 (eluted by CHCl3:MeOH = 1:1). We then treated 175 
cells with each fraction (F2, F2‐1, F2‐2 or F2‐3), at 30 μg/ml each for 6 hr and measured 176 
  
cellular ATP levels. Two fractions, F2 and F2‐1, showed significant reductions of 177 
cellular ATP levels in B16F10 cells, and the effect was much more pronounced with the 178 
F2‐1 treatment than the F2 treatment (Figure 2c). 179 
      HPLC analysis showed only two prominent peaks in F2‐1, and these peaks were 180 
much smaller in F2‐2 and F2‐3 (Figure 2d and Figure S2a,b). We noticed from the 181 
literature that these two peaks with very low polarity characteristics were most likely to 182 
be emodin and physcion, abundant anthraquinones in RPC, which also have very low 183 
polarity characteristics (Chu, Sun, & Liu, 2005). We then compared F2‐1 with 184 
commercially obtained emodin and physcion by HPLC. The retention times of the two 185 
peaks in F2‐1 (Peak A: 11.52 min, Peak B: 18.97 min) were very close to that of emodin 186 
(11.53 min) and physcion (19.04 min), respectively (Figure 2d). Furthermore, optical 187 
spectra of each peak (A or B) in F2‐1 were almost identical with that of emodin or 188 
physcion, respectively (Figure 2e). To confirm the structure of peak A and B, we analyzed 189 
F2‐1, emodin and physcion, by 1H‐NMR. The chemical shifts of each peak (A or B) were 190 
accurately matched with that of emodin or physcion, respectively, and molar ratio of A 191 
and B was approximately 1:0.28 (Figure 2f,g) (Danielsen, Aksnes, & Francis, 1992). To 192 
confirm this ratio, we compared peak areas between F2‐1 and a mixed sample of emodin 193 
and physcion, which was prepared at 1:0.28 molar ratio. The result showed that the area 194 
  
ratio of the two peaks in F2‐1 and the mixed sample were very close (Figure S3). From 195 
these results, we concluded that F2‐1 was composed of two anthraquinones, emodin and 196 
physcion (Figure 2h), at a molar ratio of approximately 1:0.28.  197 
      We then treated two cell lines with 8 μg/ml of emodin or 8 μg/ml of emodin + 198 
2.24 μg/ml of physcion (emodin: physion = 1:0.28 in molar ratio), examined the ATP 199 
levels of the cells, and found that both had similar capacities to decrease cellular ATP 200 
levels in B16F10 cells (Figure 2i). Physcion did not affect emodin's action in B16F10 201 
cells. However, the mixure of emodin and physcion appeared to reduce ATP levels in 202 
MEF cells, although this effect was not significant. This tendency was also observed in 203 
MEF cells treated with 30 μg/ml of F2‐1 (Figure 2c). From these results, we concluded 204 
that an effective ingredient in the RPC extract, which reduces ATP levels preferentially 205 
in B16F10 cells, is emodin. 206 
 207 
2.3 | Emodin suppresses cell proliferation of B16F10 cells in vitro and in vivo 208 
      We next examined the suppressive effects of emodin on B16F10 cell proliferation. 209 
As expected, 4, 8 and 16 μg/ml of emodin showed significant suppression of 210 
proliferation of B16F10 cells (Figure 3a). In contrast, only 16 μg/ml of emodin showed 211 
significant suppression on the proliferation of MEF cells. Similar suppressive effects on 212 
  
the cellular ATP levels were observed (Figure 3b, Figure S4). In these experiments, we 213 
used cisplatin as a control, which is well known to manifest severe side effects in patients, 214 
and found that cisplatin showed similar antiproliferative effects in both B16F10 and MEF 215 
cells (Figure S5a). Because its mode of action is DNA interstrand crosslinking rather than 216 
perturbation of energy homeostasis per se, cisplatin did not reduce ATP levels in both 217 
B16F10 and MEF cells (Figure S5b). Following up on emodin's ability to preferentially 218 
decrease cellular ATP levels, much more in B16F10 cells than in MEF cells, we evaluated 219 
phosphorylation (Thr172) of AMP‐activated protein kinase (AMPK). Western blot 220 
analyses showed a clear increase in phosphorylation of AMPK at 8 and 16 μg/ml 221 
of emodin in B16F10 cells, compared with MEF cells (Figure 3c). 222 
      We next examined the antiproliferative effects of emodin up to 3 days in B16F10 223 
and MEF cells (Figure 3d). 4 and 8 μg/ml emodin produced significant effects in B16F10 224 
cells (p < 0.005 and p < 0.005, respectively), and marginal or less significant effects in 225 
MEF cells (p = 0.571 and p = 0.059, respectively). It is noteworthy that 226 
cisplatin suppressed proliferation much more effectively in MEF cells than B16F10 cells. 227 
In order to evaluate emodin's antiproliferative effects on B16F10 cells in vivo, we 228 
treated mice bearing B16F10 cell‐derived tumors with emodin (50 mg kg−1 day−1), as 229 
outlined in Figure 3e. An emodin‐ treated group (n = 9) showed significant 230 
  
suppressions of tumor growth at 8, 10 and 12 days after the injection of B16F10 cells, as 231 
compared to a vehicle‐treated group (n = 9) (Figure 3f). 232 
 233 
2.4 | Emodin functions as a mitochondrial uncoupler 234 
      Because emodin decreased cellular ATP levels in B16F10 cells, we next evaluated 235 
mitochondrial functions after emodin treatment. We first evaluated the mitochondrial 236 
membrane potential (MMP) by using tetramethylrhodamine methyl ester (TMRM) and 237 
we found that the addition of emodin rapidly reduced the MMP, which dropped to levels 238 
approximately 30% of those before its addition, within only 30 min (Figure 4a) (Qu et al., 239 
2013). This effect continued up to 24 hr after its addition (Figure 4b). Notably, similar 240 
phenotypes were also observed in MEF cells. We considered two possibilities for the 241 
decrease of the MMP: inhibition of OXPHOS or proton leakage from the inner membrane 242 
space to the matrix, which would tend to decrease or enhance the oxygen 243 
consumption rate (OCR), respectively. Thus, we monitored the OCR before and 244 
following the addition of emodin; we also used carbonyl cyanide 3‐245 
chlorophenylhydrazone (CCCP), a mitochondrial uncoupler, or rotenone, a respiration 246 
inhibitor, as controls. Treatment with emodin or CCCP similarly stimulated the OCR in 247 
both cell lines, and the stimulated OCR was completely abrogated by the inhibition of the 248 
  
mitochondrial respiratory chain with rotenone and antimycin (Figure 4c). It is known that 249 
cells increase OXPHOS when faced with proton leakage in order to compensate for the 250 
lack of the proton gradient between the inner membrane space and the matrix. This notion 251 
and our results support the idea that proton leakage, but not inhibition of OXPHOS, is the 252 
underlying mechanism. ATP synthetase is a well‐known proton leaker. However, the 253 
enhancement of the OCR by emodin or CCCP was also induced in the presence of 254 
oligomcin, an inhibitor of ATP synthetase, indicating that ATP synthetase is not 255 
involved in this increased respiration (Figure 4d, Figure S6). It is also known that proton 256 
leakage can also be chemically induced by an uncoupler, such as CCCP. Indeed, emodin 257 
and CCCP acted very similarly to decrease the MMP and increase the OCR. CCCP 258 
combines protons in a proton‐rich environment and is able to pass through the cellular 259 
membrane and then provoke the release of protons in a neutral environment. For both of 260 
these to occur, the uncoupler requires two basic features, lipophilicity and weak acidity. 261 
It is notable that two parameters, pKa and logP, are very similar between emodin and 262 
CCCP (Figure 4e) (Scifinder, 2017). 263 
      We next examined the relationship between mitochondrial uncoupling and 264 
cellular phenotypes induced by emodin. We treated both B16F10 and MEF cells with 265 
three different mitochondrial uncouplers and evaluated their effects. Treatment with 266 
  
CCCP, carbonyl cyanide 4‐(trifluoromethoxy)phenylhydazone (FCCP) and 2,4‐267 
dinitrophenol (DNP) all decreased MMP similarly to what we observed with the emodin 268 
treatment (Figure 4f, Figure S7). FCCP and DNP marginally and emodin and CCCP 269 
significantly reduced ATP levels (Figure 4g), and emodin and all three uncouplers 270 
preferentially showed antiproliferative effects on B16F10 cells, opposed to MEF cells 271 
(Figure 4h). Furthermore, inhibition of mitochondrial respiratory chain complex Ⅰ with 272 
rotenone or metformin did not show preferential ATP reduction and 273 
antiproliferation effects in B16F10 cells rather than MEF cells (Figure 4i,j). It is notable 274 
that both inhibitors reduced the ATP levels more potently in MEF cells than in B16F10 275 
cells (Figure 4i). From these lines of evidence, we concluded that emodin functions as a 276 
mitochondrial uncoupler (Attene‐Ramos et al., 2013; Betina & Kuzela, 1987; Ubbink‐277 
Kok, Anderson, & Konings, 1986). 278 
 279 
2.5 | Glycolytic reserve of B16F10 cells is poor compared with MEF cells 280 
      Given the enhanced sensitivity of B16F10 cells to emodin, we next focused on 281 
another energy‐producing system, glycolysis, in cells treated with uncouplers. First, we 282 
measured glucose consumption in media and found that emodin and three mitochondrial 283 
uncouplers drastically enhanced glucose consumption in MEF cells, whereas only a weak 284 
  
increase was observed with B16F10 cells (Figure 5a). Next, we monitored the 285 
extracellular acidification rate (ECAR) followed by the addition of mitochondrial 286 
uncouplers and 2‐deoxy‐D‐glucose (2‐DG). Because of the autofluorescence of emodin, 287 
we could not obtain reliable ECAR data for cells treated with emodin in this system. 288 
Nevertheless, CCCP, FCCP and DNP dramatically increased the ECAR of MEF cells, up 289 
to three to five times higher than the baseline points before their addition, indicating an 290 
obvious increase in glycolysis because of uncoupling (Figure 5b,c right). This 291 
compensatory activation of glycolysis in the face of mitochondrial dysfunctions, termed 292 
the “glycolytic reserve,” could potentially maintain cellular ATP levels. By contrast, with 293 
B16F10 cells, the enhancements of ECAR were only 50%–80% compared with baseline 294 
levels (Figure 5b,c, left). It is notable that HeLa and A549 cells appeared to have more 295 
glycolytic reserve than B16F10 cells (Figure S8a). Consistently, emodin and all three 296 
uncouplers produced smaller effects on HeLa and A549 cells than on B16F10 cells 297 
(Figure S8b). 298 
      Next, we treated B16F10 and MEF cells with emodin in various concentrations of 299 
glucose and measured ATP levels by a luciferase‐based assay. The result showed that, in 300 
all concentrations of glucose (200, 100, 50 and 0 mg/dl), cellular ATP levels of B16F10 301 
cells treated with 8 μg/ml of emodin for 6 hr clearly decreased (Figure 5d, left). In contrast, 302 
  
MEF cells could not keep their ATP levels only under the glucosefree conditions (in 303 
correct, this medium included FBS‐contained glucose) by treatment of 8 μg/ml of emodin 304 
for 6 hr (Figure 5d, right). And this reduction of ATP levels could not be rescued by 305 
treatment of pyruvate, a metabolite for TCA cycle (Figure S9a). Furthermore, treatment 306 
with 8 μg/ ml emodin suppressed the proliferation of MEF cells under glucose‐free 307 
condition (Figure S9b,c). These results suggest that the resistance of MEF cells to emodin 308 
depends on the glycolytic reserve. 309 
 310 
3 | DISCUSSION 311 
      Cancer cells use higher amounts of energy for their enhanced proliferation, as 312 
compared with nonmalignant normal cells, indicating the presence of cancer‐specific 313 
energy metabolisms, for example, enhanced glycolysis or Warburg effects. The 314 
corresponding cancer‐specific energy metabolisms have long been considered as 315 
potential targets for cancer therapy. In this regard, the down‐regulation of ATP 316 
production might be a simple and effective strategy for limiting the proliferation of cancer 317 
cells. Indeed, “metformin,” which functions as an inhibitor of mitochondrial respiratory 318 
chain complex I, has been evaluated in clinical trials for cancer therapy. 319 
      We have collected more than 1,000 plant extracts and used them as sources of 320 
  
chemicals with potential benefits for human health; we have previously identified 321 
“Garcinielliptone HC” from hop flower extracts as a potential prophylactic 322 
for Alzheimer's Disease (Sasaoka et al., 2014). We then hypothesized that some plant 323 
extracts might contain chemicals that can reduce ATP levels in a cancer cell‐specific 324 
manner. We then screened the extracts and found that one extract, which was derived 325 
from rhizomes of Polygonum cuspidatum (RPC), had such activities; the extract 326 
decreased cellular ATP levels in rapidly proliferating melanoma B16F10 cells but not 327 
normal mouse embryonic fibroblast (MEF) cells. Using several analytical techniques, we 328 
identified the principle active ingredient as “emodin,” an anthraquinone. “Emodin” has 329 
been repeatedly purified from many different plant extracts and been reported to elicit 330 
many cellular effects, for example, anticancer, hepatoprotective, anti‐inflammatory, 331 
antimicrobial and antioxidant activities (Dong et al., 2016). These observations surprised 332 
us, because only one plant extract, RPC, effectively lowered ATP levels in B16F10 cells. 333 
These results indicate that RPC extract contains much more emodin than any other plant 334 
extracts tested. 335 
      Emodin as well as RPC extract showed very promising characteristics as potential 336 
agents for cancer therapy. Both dramatically reduced ATP levels in B16F10 cells but not 337 
in MEF cells. Concomitantly, both inhibited proliferation of B16F10 cells more potently 338 
  
than MEF cells. These differential inhibitory effects present a sharp contrast to cisplatin, 339 
an anticancer drug widely used in current clinical treatments. Cisplatin did not reduce 340 
ATP levels in both B16F10 cells and MEF cells; moreover, it inhibited proliferation of 341 
both cells. It is notable that the antiproliferative effects of cisplatin were even greater on 342 
MEF cells than on B16F10 cells, which may explain some of the severe side effects of 343 
cisplatin (Tsang, Al‐Fayea, & Au, 2009). With this in mind, emodin and RPC extract 344 
might produce milder side effects than cisplatin. The antiproliferative effects of emodin 345 
were also confirmed in an in vivo assay, using a mouse melanoma model in which 346 
B16F10 cells were subcutaneously implanted. Administrations of emodin (50 mg kg−1 347 
day−1) to the mice significantly suppressed the tumor growth of B16F10 cells. These 348 
results support the idea that ATP down‐regulation in cancer cells is a potential 349 
therapeutic strategy to suppress cancer cell proliferation. 350 
      What is molecular basis of the antiproliferative effect of emodin? Emodin has 351 
been shown to produce oxidative stress in cells (Qu et al., 2013; Su, Chang, Shyue, & 352 
Hsu, 2005). We thus examined the effect of N‐acetyl‐L‐cysteine (NAC), a well‐known 353 
antioxidant, on the antiproliferative effects of emodin. Treatment of 1 mM NAC, which 354 
clearly suppressed the cytotoxicity induced by H2O2, did not diminish the 355 
antiproliferative effects of emodin at all (Figure S10). We further observed that emodin 356 
  
treatment led to stimulation of the OCR, which is usually accompanied by an elevation 357 
of the MMP. However, emodin reduced the MMP. These results indicate that emodin 358 
functions as a mitochondrial uncoupler. Consistently, other mitochondrial uncouplers, 359 
CCCP, FCCP and DNP, also showed similar effects on the OCR and MMP. These 360 
uncouplers also reduced cellular ATP levels and showed antiproliferative activities, and 361 
both were prominent on B16F10 cells, but not on MEF cells. Furthermore, the chemical 362 
profiles of emodin fit well with those of the uncouplers or the ionophore. Taken together, 363 
we conclude that the antiproliferative effects of emodin are due to function as a 364 
mitochondrial uncoupler. Some of the studies reported that emodin provokes an 365 
antiproliferative activity or cell death in cancer cell lines and also mentioned various 366 
molecule behaviors in cancer cells treated with emodin. For example, an activation of 367 
mitochondrial apoptotic pathway, stimulated FAS ligand pathway, decreased gene 368 
expression of C‐MYC, lowered signals related to the cell stemness or reduced 369 
protein level of ERα (Dong et al., 2016). Nevertheless, in the cancer cells treated with 370 
emodin, the initial event at molecular level had been unclear. Furthermore, no studies 371 
focused on emodin's noteworthy actions which we observed in this study, mitochondrial 372 
uncoupling and ATP down‐regulation, as a potential target to overcome cancer 373 
malignancy. 374 
  
      The ability of uncouplers to lower ATP levels directed our attention to the 375 
preferentially suppression of growth of cancer cells such as B16F10, as compared with 376 
MEF cells. Emodin and other uncouplers were able to enhance glucose consumptions in 377 
both B16F10 cells and MEF cells, but the effects were much stronger in MEF cells (300% 378 
to 450% enhancements) than in B16F10 cells (170% to 190% 379 
enhancements). Consistently, CCCP, FCCP and DNP were able to enhance ECAR much 380 
more strongly in MEF cells than in B16F10 cells (Recall that we were unable to conduct 381 
the ECAR assay with emodin because of its autofluorescence). Furthermore, MEF cells 382 
could not sustain their ATP levels after the emodin stimulation under the very low 383 
concentrations of glucose. These results indicated that B16F10 cells have much 384 
less “glycolytic reserve” than MEF cells and thus B16F10 cells were much more sensitive 385 
to emodin or other uncouplers than MEF cells, resulting in a more pronounced reduction 386 
in ATP levels and suppression of the growth of B16F10 cells than MEF cells. From these 387 
results, we concluded that the “glycolytic reserve” is a major determinant in maintaining 388 
cellular ATP levels in response to mitochondrial uncouplers. It is notable that many 389 
tumors grow in hypoxic conditions, indicating that such hypoxic cancer cells maximally 390 
use glycolysis and thereby maintain less glycolytic reserve, which would further enhance 391 
the Warburg effect. We thus propose ATP down‐regulation by mitochondrial uncoupling 392 
  
as a challenging strategy for the cancer therapy, alone or in combination with other cancer 393 


















4 | EXPERIMENTAL PROCEDURES 411 
4.1 | Cell culture 412 
      Both cell lines, B16F10 (obtained from Riken Bioresource Center Cell Bank) and 413 
MEF (naturally immortalized mouse embryonic fibroblasts, kindly provided by Professor 414 
Shin Yonehara (Kyoto University)), were cultured in Roswell Park Memorial Institute 415 
medium 1640 (RPMI 1640, NACALAI TESQUE). HeLa (also kindly provided by 416 
Professor Shin Yonehara (Kyoto University)) and A549 (obtained from Riken 417 
Bioresource Center Cell Bank) cell lines were maintained in Dulbecco Modified Eagle 418 
medium (DMEM‐high glucose, NACALAI TESQUE). Cell culture was carried out with 419 
10% fetal bovine serum (Sigma) in a humidified incubator with 5% carbon dioxide (CO2) 420 
at 37℃. All cells were routinely tested for Mycoplasma using MycoAlert (Lonza). 421 
 422 
4.2 | Plant extracts and reagents 423 
      Crude plant extracts were purchased from an importer of Chinese Medicine. 424 
Reagents were as follows: emodin (Tokyo Chemical Industry), physcion (LKT 425 
Laboratories), dimethyl sulfoxide (DMSO) (NACALAI TESQUE), polyethylene 426 
glycol 400 (PEG400) (HAMPTON), cisplatin (CDDP) (Nihon Kayaku), rotenone 427 
(Sigma), antimycin (Sigma), oligomycin (Sigma), carbonyl cyanide 3‐428 
  
chlorophenylhydrazone (CCCP) (NACALAI TESQUE), carbonyl cyanide 4‐429 
(trifluoromethoxy) phenylhydazone (FCCP) (Santa Cruz Biotechnology), 2,4‐430 
dinitrophenol (DNP) (Sigma), metformin (Sigma) and 2‐ deoxy‐D‐glucose (2‐DG) 431 
(NACALAI TESQUE). 432 
 433 
4.3 | Extracellular flux analysis 434 
      Extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) 435 
were measured by Seahorse Extracellular Flux Analyzer 96 (Seahorse XF96 Analyzer, 436 
Agilent) according to the manufacture's protocol. Briefly, cells were plated at 1x104 437 
cells per well in a Seahorse XF96 Cell Culture Microplate and were cultured for 438 
approximately 24 hr. Then, media were changed to media with lower pH buffering 439 
capacity (Agilent 103676‐100) followed by placing the plate in Seahorse XF96 440 
Analyzer. Emodin or other reagents were injected at defined time points automatically. 441 
After the measurements, cells were fixed (20% formaldehyde, 2% glutaraldehyde, PBS 442 
(without Ca2+ and Mg2+) and stained with Hoechst 33342 (Invitrogen). Cell numbers 443 
were counted by counting the number of nuclei using an ArrayScan VTI High 444 
Content Platform (Thermo Fisher Scientific); then, ECAR and OCR were normalized 445 
by the cell number in each well. 446 
  
 447 
4.4 | ATPase activity assay 448 
      Cells cultured in 100‐mm dishes were washed with ice‐cold PBS and then 449 
harvested in 500 μl of ice‐cold ATPase buffer (50 mM Tris‐HCl, 250 mM sucrose, 5 mM 450 
MgCl2, 0.5 mM EDTA, 0.3 mM DTT) using a scraper. Cells were lysed by repeated 451 
passage through a 27 G needle attached to a 1cc syringe on ice, followed by centrifugation 452 
at 13,000 g, 4℃ for 10 min. The supernatants were transferred to new tubes, and aliquots 453 
were subjected to a bicinchoninic acid assay (BCA, NACALAI TESQUE) to quantify 454 
protein concentrations. The cell lysates were diluted with ATPase buffer to 1 μg of total 455 
protein in 20 μl and incubated at 37℃ for 15 min. After the incubations, 100 μM [γ‐32P] 456 
ATP (18.5 GBq/mmol) in 20 μl of ATPase assay buffer (1 mM HEPES[pH 7.4], 2.5 457 
mM KCl, 5 mM MgCl2, 50 μM ATP, 15 mM DTT) was added to monitor ATP hydrolysis 458 
reactions for 20 min. Then, 200 μl of ice‐cold 8% TCA was added to quench the reactions, 459 
followed by the additions of 50 μl of solution A (3.75% ammonium molybdate, 0.02 M 460 
silicotungstic acid in 3 N H2SO4) and 300 μl of n‐butyl acetate to the reactions. The 461 
samples were thoroughly mixed and centrifuged at 15,000 g for 5 min at room 462 
temperature. After the phase separation, 200 μl aliquots of the upper layer were mixed 463 
with 2 ml of clear‐sol Ⅱ, and radioactivity, corresponding to 32P release, was 464 
  
quantitated with a liquid scintillation counter (PerkinElmer). The relative radioactivities 465 
were shown as results. 466 
 467 
4.5 | Evaluations of mitochondrial membrane potential 468 
      Cells plated on a collagen‐coated glass‐bottom 35‐mm dish (Mat‐Tek) were 469 
treated with 50 nM of tetramethylrhodamine methyl ester (TMRM) (Invitrogen) in phenol 470 
red‐free RPMI 1640 (NACALAI TESQUE) with 10% FBS for 30 min at 37℃. Imaging 471 
was carried out with a Nikon Ti‐E inverted microscope using a 60× objective (Nikon; CFI 472 
Plan Apo λ 60× oil: NA 1.40) which was controlled with NIS‐Elements (Nikon). The 473 
following filter sets (Semrock) were used: for imaging of TMRM, 562/40 excitation 474 
filter—dichroic mirror FF593—641/75 emission filter; and for imaging of Hoechst 475 
33342, 405/10 excitation filter—dichroic mirror FF495‐520/35 emission filter. 476 
Fluorescence emissions from samples were captured with a Zyla4.2 sCMOS 477 
camera (ANDOR). Throughout the imaging, cells were maintained at 37℃ with a 478 
continuous supply of a mixture of 95% air and 5% CO₂ using a stage‐top incubator (Tokai 479 
Hit). The imaging results were quantified by MetaMorph (Molecular Devices). 480 
 481 
4.6 | Luciferase‐based ATP quantification 482 
  
      Cells were plated in a 24‐well plate and were cultured for approximately 24 hr 483 
before drug treatment. At each period (6 or 24 hr), culture media were removed and cells 484 
were gently washed with PBS. 200 μl of Glo Lysis Buffer (1×, Promega) was added to 485 
each well, and cells were incubated for 5 min. Then, the plate was agitated with a plate‐486 
shaker for 1 min and the supernatants were transferred to 96‐well plate. Bioluminescence 487 
of each well was measured by an ARVO multilabel counter (PerkinElmer) using ATP 488 
assay reagent for cells (ToyoB‐net). Each value of bioluminescence was normalized by 489 
the protein content, respectively, using a Protein Assay Bicinchoninate Kit 490 
(NACALAI TESQUE).  491 
 492 
4.7 | Bligh–Dyer method 493 
      Seventy to eighty milligram of crude extract was suspended in 3.8 ml of solvent 494 
1 (chloroform: methanol: water, 1 ml: 2 ml: 0.8 ml) by vortexing. After an incubation for 495 
10 min at room temperature, 2 ml of solvent 2 (chloroform: water, 1 ml: 1 ml) was added 496 
and mixed by vortexing, and then incubated for 15 min at room temperature. The mixture 497 
was centrifuged at 9,100 g for 15 min at 4℃. The upper layer (water‐soluble fraction: F1) 498 
and the lower layer (lipid‐soluble fraction: F2) were separated and dried. The dried 499 
fractions were weighed. Of the crude extract, approximately 70% and 10% in F1 and F2 500 
  
by weight, respectively, were recovered, whereas the remaining 20% was left in an 501 
insoluble‐intermediate layer. 502 
 503 
4.8 | Solid phase extraction 504 
      The dried lipid‐soluble fraction (F2) from the Bligh–Dyer method was dissolved 505 
in chloroform, and further separation was carried out by a Sep‐Pak Plus Silica column 506 
(Waters). Before loading, dissolved F2 was filtered through an Acrodisc LC 25‐mm 507 
Syringe Filter with 0.45 μm PVDF Membrane (Pall corporation). The filtered F2 was 508 
loaded into the column and was eluted with 100% chloroform (F2‐1), followed 509 
by chloroform: methanol (4:1) (F2‐2) and chloroform: methanol (1:1) (F2‐3). Each 510 
fraction was dried and dissolved in dimethyl sulfoxide (DMSO) and then subjected to the 511 
biological assay.  512 
 513 
4.9 | HPLC analysis 514 
      Reverse‐phase HPLC separations were carried out with an Alliance 2690 HT 515 
(Waters), 996 Photodiode Array Detector (Waters) and Mightysil RP‐18 150–4.6 516 
(particle size 5 μm) HPLC column (Kanto Chemical). 50 μl of filtered samples was 517 
applied to the column, which was eluted with a gradient from 0.1% TFA in acetonitrile: 518 
  
0.1% TFA in water (40:60) to (90:10) for 30 min. The flow rate was 1.0 ml/min, and 519 
the column temperature was maintained at 40℃. 520 
 521 
4.10 | 1H‐NMR 522 
      1H‐NMR spectra were recorded on a JNM‐AL 400 (JEOL) at 400 MHz. 523 
Chemical shifts were reported relative to Me4Si (δ 0.00) in DMSO‐d6. Multiplicity was 524 
indicated by one or more of the following: s (singlet); brs (broad singlet); and 525 
d (doublet). 526 
 527 
4.11 | Trypan blue dye‐exclusion test 528 
      After the drug treatment, both floating and attaching cells were harvested into a 529 
tube. The total cell suspensions from each well were centrifuged at 3,420 g for 5 min; 530 
then, the pellets were resuspended in an aliquot of PBS. 10 μl of each respective cell 531 
suspension was mixed with 10 μl of trypan blue solution (0.4%, Gibco by Life 532 
Technologies), followed by cell counting using a TC10 Automated Cell Counter (Bio‐533 
Rad).  534 
 535 
4.12 | Western blotting 536 
  
      Cells were harvested in RIPA buffer (5 mM EDTA (Dojindo), 0.1% CHAPS 537 
(Dojindo), 1 mM NaF (NACALAI TESQUE), 1 mM NaVO4 (NACALAI TESQUE), 1 538 
mM NaPPi (Dojindo), 0.5 mM PMSF (NACALAI TESQUE), 1× protease inhibitor 539 
cocktail (NACALAI TESQUE), 0.5 mM DTT (NACALAI TESQUE), 5 mM β‐540 
glycerophosphate (Sigma)), and were sonicated on ice followed by centrifugation at 541 
4℃ at 20,400 g for 5 min. The supernatant was used for protein concentration 542 
determination by the BCA assay (NACALAI TESQUE). Ten μg of protein was loaded 543 
per well, was separated by 10% SDS‐PAGE and was transferred to 544 
polyvinylidene fluoride membranes (Millipore). Primary antibodies were the following: 545 
anti‐phospho‐AMPKα (Thr172) (1:1,000, Cell Signaling Technology, #2535S), anti‐546 
AMPKα (1:1,000, Cell Signaling Techonology, #2603S), anti‐actin (1:1,000, Millipore, 547 
MAB1501), anti‐p53 (FL‐393) (1:200, Santa Cruz Biotechnology, sc‐6243) and anti‐p21 548 
(C‐19) (1:200, Santa Cruz Biotechnology, sc‐397). Secondary antibodies labeled with 549 
HRP were purchased from GE Healthcare, and signals were visualized by enhanced 550 
chemiluminescence (GE Healthcare).  551 
 552 
4.13 | Tumor growth assay 553 
      B16F10 cells cultured in 100‐mm dishes were treated with 0.25% trypsin and 554 
  
harvested in culture medium (RPMI1640 supplemented with 10% FBS); then, the cells 555 
were centrifuged at 160 g for 3 min, and the pellet was resuspended in PBS to wash out 556 
the culture medium by centrifugation. After the washing, the pellet was suspended in a 557 
small amount of PBS followed by cell counting, and the cell concentration was adjusted 558 
to 4 × 106 cells/ml by dilution in PBS. B16F10 cells were transplanted into the right flank 559 
of C57BL/6N mice (female, 7–8 weeks old) subcutaneously (2 × 105 cells/ mouse, Day 560 
0). Starting on the following day (Day 1), emodin dissolved in a mixture of DMSO and 561 
PEG400 (1:1) was administrated intraperitonealy at 50 mg/kg of body weight per day for 562 
12 days. On Days 8, 9 and 10, tumor sizes, length (A mm), width (B mm) and height (C 563 
mm) were measured, and the tumor volume was calculated by A × B×C × 0.52. All 564 
animal studies were approved by the Animal Care and Use Committee of Kyoto 565 
University. 566 
 567 
4.14 | Glucose consumption 568 
      Cells were plated in a 24‐well plate and were cultured for approximately 24 hr, 569 
followed by treatments with 200 μl of drug‐containing medium for 4 hr. The cultured 570 
media supernatants were harvested and centrifuged at 3,420 g for 5 min. 571 
Glucose concentrations in the supernatants were determined by a Glucose CⅡ Assay Kit 572 
  
(Wako) according to the manufacturer's instructions. Possible direct effects of each 573 
compound on the Glucose CⅡ reactions were evaluated by using compound‐574 
containing media without cells, in parallel mock wells of the 24‐well plate. 575 
 576 
4.15 | Statistical analysis 577 
      The statistical significance was evaluated using Student's t test or Dunnett's test, 578 
where appropriate. 579 
 580 
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FIGURE LEGENDS 777 
 778 
FIGURE 1  779 
A plant extract from rhizomes of Polygonum cuspidatum preferentially 780 
decreases cellular adenosine triphosphate (ATP) levels in B16F10 cells but not 781 
MEFs.  782 
(a) The proliferative propensities of B16F10 and MEF cell lines were compared by 783 
mean values of total cell numbers at the respective time points. n = 3 at each point. (b 784 
and c) Analyses of energy metabolism. Extra cellular acidification rate (ECAR)  785 
(b) and oxygen consumption rate (OCR) (c) were measured using Seahorse XF96 786 
Analyzer (Agilent). ECAR of glycolysis: (ECAR of basic state) − (ECAR after treatment 787 
with 100 mM of 2‐deoxyglucose). OCR of mitochondrial respiration: (OCR of basic 788 
state) − (OCR after the treatment with respiration inhibitors, rotenone and antimycin (3 789 
μM each)). B16F10: n = 5, MEF: n = 3.  790 
(d) Two cell lines were stained with tetramethylrhodamine methyl ester (TMRM), and 791 
the mitochondrial membrane potential (MMP) in the basic state for each cell line was 792 
compared by measuring the intensity of fluorescence using microscopic analysis. 793 
Fluorescence intensities are presented as mean values of respective cells in each cell 794 
  
line; B16F10, n = 22. MEF, n = 28.  795 
(e) ATPase activities of whole cell lysates from B16F10 and MEF cells were measured 796 
by a modified molybdate assay. Each cell lysate was diluted to the same concentration 797 
of total protein, and ATP hydrolysis reactions were carried out. The results are 798 
presented as means of three ATP hydrolysis reactions.  799 
(a‐e) Error bars indicate standard deviations. (b–e) *p < 0.05, ***p < 0.005, by 800 
Student's t test.  801 
(f) The two cell lines, B16F10 and MEF, were cultured with each plant extract at 100 802 
μg/ml for 6 hr (A: Rhizoma Polygonum cuspidatum, B: Rhizoma Cortex periplocae, C: 803 
Fructu Cucurbitae moschatae, D: Flos Chrysanthem, E: Semen Lepidii) and subjected 804 
to luciferase‐based ATP quantifications. The 805 
results were normalized by the protein amount in each well and showed as averages 806 
and standard deviations. *p < 0.05, ***p < 0.005, (B16F10, vs. DMSO), †p < 0.05, ††p 807 
< 0.01 (MEF, vs. DMSO), by Dunnett's test. N.S., not significant 808 
 809 
FIGURE 2  810 
Emodin is the responsible ingredient in the RPC extract.  811 
(a) Schematic flow of the polarity‐based fractionations of the extract from rhizome of 812 
  
Polygonum cuspidatum. The bioactivities that lowered adenosine triphosphate (ATP) 813 
levels in cells were found in fractions F2 and F2‐1, as shown in bold characters. (b 814 
and c) Luciferase‐based ATP quantifications. Before the measurements, B16F10 815 
cells and MEF cells were treated with DMSO, #1 (crude, lot.1), #2 (crude, lot.2), #2‐816 
F1 or #2‐F2, for 6 hr in (b). In (c), cells were cultured with the indicated fractions 817 
purified from #2 (crude, lot.2), F2, F2‐1, F2‐2, F2‐3 or DMSO, for 6 hr. The results 818 
show means with standard deviations. ***p < 0.005. (B16F10, vs. DMSO), ††p < 0.01, 819 
†††p < 0.005 (MEF, vs. DMSO), by Dunnett's test. N.S., not significant. (d and e) 820 
Reverse‐phase HPLC analysis of F2‐1 from the SPE and commercially available 821 
standard compounds, emodin and physcion. Acetonitrile‐dissolved samples were 822 
applied to a Mightysil RP‐18 GP 150–4.6 (5 μm) column and eluted with a linear 823 
gradient of acetonitrile, 40% to 90% for 30 min, in water with 0.1% trifluoroacetic acid 824 
(TFA).  825 
(d) Chromatograms of each sample at 254 nm are shown. (e) Ultraviolet –visible 826 
absorption spectra of each sample (210 nm−600 nm) are shown.  827 
(f and g) 1H‐NMR (DMSO‐d6) analysis of F2‐1 and commercially available 828 
standards, emodin and physcion. (h) Chemical structures of the anthraquinones, 829 
emodin and physcion.  830 
  
(i) Luciferase‐based ATP quantifications. B16F10 cells and MEF cells were treated 831 
with DMSO or standard chemicals (emodin (8 μg/ml) or emodin (8 μg/ml) + physcion 832 
(2.24 μg/ml) (1:0.28 molar ratio)), for 6 hr, followed by ATP quantifications in each 833 
lysate. The result shows the average of four wells, and error bars indicate standard 834 
deviations. ***p < 0.005 (versus DMSO), by Dunnett's test. N.S., not significant 835 
 836 
FIGURE 3  837 
Emodin suppresses cell proliferation of B16F10 cells in vitro and in vivo.  838 
(a and b) B16F10 cells and MEF cells were treated with or without the indicated 839 
concentrations of emodin for 24 hr followed by a cell proliferation assay using a trypan 840 
blue dye‐exclusion test (left), and 6‐hr treatment was carried out for an evaluation of 841 
adenosine triphosphate (ATP) levels using a luciferase assay (right). Each result shows 842 
the average of three independent trials, and error bars indicate standard errors. 843 
Statistical analyses were carried out using total cell numbers. *p < 0.05, ***p < 0.005 844 
(B16F10, vs. DMSO), †p < 0.05, ††p < 0.005 (MEF, vs. DMSO), by Dunnett's test. 845 
N.S., not significant.  846 
(c) Western blot analyses using whole cell lysates of each cell line. Before lysis, each 847 
cell line was treated with DMSO, emodin (8 or 16 μg/ml) or cisplatin (CDDP) (30 or 100 848 
  
μM) for 6 hr. Phosphorylation of AMPK at threonine 172 and expression levels of 849 
AMPKα, p53 and actin, were evaluated.  850 
(d) B16F10 cells (left) and MEF cells (right) were cultured with DMSO, emodin (4 or 8 851 
μg/ml) or CDDP (1 or 2 μM), for three days. At the respective time point days 0, 1, 2 852 
and 3, total cell numbers per well were recorded. Each result shows the average of 853 
three independent trials, and error bars indicate the standard error. The p value 854 
indicates the statistical result of Dunnett's test (vs. DMSO at Day 3).  855 
(e) Schematic drawing of the experimental design for the tumor growth assay. 856 
C57BL/6N (female) mice were transplanted with B16F10 cells (2 × 105 cells in PBS), 857 
and intraperitoneal administrations of vehicle or emodin (50 mg/kg body weight) were 858 
initiated following day.  859 
(f) Monitoring tumor growth in mice. The result shows each tumor volume per mouse, 860 
with the horizontal bar indicating the average, at Days 8, 10 and 12. *p < 0.05, **p < 861 
0.01 (Vehicle vs. EMO), by Student's t test 862 
 863 
FIGURE 4  864 
Emodin functions as a mitochondrial uncoupler.  865 
(a) Cell lines were cultured on collagen‐coated glass‐bottom dishes for 866 
  
approximately 24 hr, and medium was replaced by fluorescent dye‐containing media 867 
(50 nM of TMRM, 1 μg/ml of Hoechst 33342, phenol red(−)) followed by incubation at 868 
37℃ for 30 min. The fluorescence images representing MMPs, before and after the 869 
addition of emodin (8 μg/ml, final),were captured, and each fluorescence intensity per 870 
cell was quantified using MetaMorph (Molecular Devices). ***p < 0.005 (B16F10, vs. 0 871 
min),†††p < 0.005 (MEF, vs. 0 min), by Dunnett's test.  872 
(b) In parallel, dishes with each respective cell line were subjected to a preliminary 873 
treatment 874 
with DMSO or emodin (8 μg/ml) for 24 hr, and the respective intensity of TMRM was 875 
compared using the same analysis as in (a) to yield the result at 24 hr. The results are 876 
presented as box‐and‐whisker plots. ***p < 0.005 (vs. DMSO) by Student's t test.  877 
(c and d) The effect of emodin on mitochondrial respiration was evaluated by Seahorse 878 
XF96 Analyzer. Cells were cultured for approximately 24 hr, and growth medium was 879 
replaced by XF RPMI 1640‐based medium (bicarbonate‐free, Seahorse). In (c), 880 
measurements of the OCR were carried out with the following initial injections: emodin 881 
(8 μg/ml, final), CCCP (5 μM, final) or rotenone (0.3 μM: final). The second injection 882 
was a mixture of complex Ⅰ inhibitors (rotenone + antimycin, 3 μM each, final). 883 
Respective results represent the average of five wells, and error bars indicate standard 884 
  
deviations. In (d), the first injection was oligomycin (3 μM: final), which was followed by 885 
the second injections: emodin (8 μg/ml, final) or CCCP (5 μM, final); a third injection 886 
consisted of a mixture of complex Ⅰ inhibitors (rotenone + antimycin, 3 μM each, 887 
final). Each result represents the average of 5 wells, and error bars indicate standard 888 
deviations.  889 
(e) Calculated values from the database (SciFinder), of pKa and logP.  890 
(f) MMPs of two cell lines, before and after the addition of emodin, uncouplers (CCCP, 891 
FCCP or DNP) or CDDP, were evaluated using TMRM (50 nM) and Hoechst 33342 (1 892 
μg/ml). Scale bar, 50 μm. In this figure, the MPP brightness of MEF cells was 893 
enhanced to clarify the differences before and after the injection of uncouplers. The 894 
unenhanced images are shown in Figure S7.  895 
(g and h) Cell lines were treated with DMSO, emodin, uncouplers (CCCP, FCCP or 896 
DNP) or CDDP, for 6 hr followed by luciferase‐based ATP quantification (g), and in 897 
the case of 24‐hr treatments, cells were subjected to a trypan blue dye‐exclusion 898 
test (h). Each vertical bar indicates the average of three wells, and error bars indicate 899 
standard deviations. *p < 0.05, ***p < 0.005 (B16F10, vs. DMSO), †p < 0.05, †††p < 900 
0.005 (MEF, vs. DMSO), by Dunnett's test.  901 
(i and j) Cell lines were treated with DMSO or complex Ⅰ inhibitors (rotenone or 902 
  
metformin) for 6 hr, followed by luciferase‐based ATP quantification (i), and in case of 903 
the 24‐hr assay, total and living cell numbers were assessed by a trypan blue dye‐904 
exclusion test (j). Results indicate mean values, and error bars indicate standard 905 
deviations. ***p < 0.005 (B16F10, vs. DMSO), †††p < 0.005. (MEF, vs. DMSO), by 906 
Dunnett's test. Statistical analyses were carried out using total cell numbers in (h, j) 907 
 908 
FIGURE 5  909 
Glycolytic reserve of B16F10 cells is poor compared with that of MEF cells.  910 
(a) B16F10 and MEF cells were cultured in 24‐well plates for approximately 24 hr, 911 
and the growth medium was replaced by fresh medium containing DMSO, emodin (8 912 
μg/ml), CCCP (5 μM), FCCP (3.5 nM), DNP (150 μM) or CDDP (30 μM), respectively. 913 
After incubation for 4 hr, respective culture media were collected, and glucose 914 
concentrations were measured by the glucose CII test (Wako). The results were 915 
normalized to the attached cell number for each well. The data represent averages of 916 
four wells, and error bars indicate standard deviations. ***p < 0.005 (B16F10, vs. 917 
DMSO), †††p < 0.005 (MEF, vs. DMSO), by Dunnett's test. N.S., not significant.  918 
(b) CCCP’s effect on glycolysis was evaluated by monitoring ECAR using Seahorse 919 
XF96 Analyzer. Approximately 24 hr after plating, cells were treated with the indicated 920 
  
concentrations of CCCP (2.5 or 5 μM, final) for the initial injections, followed by a 921 
second injection of 2‐DG (100 mM, final). Results are shown as ECAR per 1 × 104 922 
cells, which represent the mean values of four 923 
wells. Error bars show standard deviations.  924 
(c) Uncouplers’ effects on glycolysis were evaluated by monitoring ECAR using 925 
Seahorse XF96 926 
Analyzer. Two cell lines were treated with the indicated concentrations of mitochondrial 927 
uncouplers (CCCP, FCCP, DNP), CDDP (30 μM) or DMSO for the initial injections, 928 
followed by a second injection of 2‐DG (100 mM, final). Results are shown as ECAR 929 
per 1 × 104 cells, which represent the mean values. Error bars show standard 930 
deviations.  931 
(d) B16F10 and MEF cells were treated with DMSO or emodin (8 μg/ml) for 6 hr, with 932 
the indicated concentrations of glucose (0, 50, 100 or 200 mg/dl) (in correct, this 933 
medium included FBS‐contained glucose), and were subjected to cellular adenosine 934 
triphosphate (ATP) quantification using the luciferase assay. Each value for the 935 
luciferase assay was normalized by the protein amount in each well. The data 936 
represent mean values, and error bars indicate standard deviations. *p < 0.05, ***p < 937 
0.005, by Student's t test (vs. DMSO). N.S., not significant.  938 
  
(e) A model of energy balance in each cell line, under the two different conditions. In 939 
basic conditions, B16F10 cells produce and consume a large amount of ATP. In the 940 
presence of a mitochondrial uncoupler, this cell line cannot maintain its energy state by 941 
relying on glycolysis, because of the poor glycolytic reserve. In contrast, because the 942 
turnover of ATP in MEF cells is slow and basal glycolysis is very low, their glycolytic 943 
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28 Emodin H-2Physcion H-2
F2-1 (¹H-NMR)(DMSOd₆)
Commercially available standards (¹H-NMR)(DMSO-d₆)
Atom Emodin (ppm) Physcion (ppm)
OH - 1/8 12.03 (brs) / 12.09 (brs) 12.11 (brs) / 12.11 (brs)
H - 7 7.16 (brs) 7.22 (brs)
H - 5 7.48 (brs) 7.54 (brs)
H - 4 7.10 (d, J = 2.6 Hz) 7.21 (d, J = 2.3 Hz)
H - 2 6.57 (d, J = 2.6 Hz) 6.89 (d, J = 2.3 Hz)
H (Me) 2.41 (s) 2.44 (s)
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SC, B16F10 Measured tumor volumes
IP, EMO (50 mg /kg /Day) or Vehicle


































































































































































































































































































































































































































































































DMSO EMO 8 
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B16F10  2.5 μM
B16F10  5 μM
MEF  2.5 μM







































































































































































































Supporting Information Figures 
 
 
             
 
Figure S1 – HeLa and A549 cells exhibited lower glycolysis and oxygen consumption 
rate compared to B16F10 cells. 
 (A)(B) Analysis of energy metabolism. ECAR (A) and OCR (B) were measured by a 
XF96 system (Seahorse). ECAR of glycolysis: (ECAR of basic state) − (ECAR after 
treatment with 100 mM of 2-deoxyglucose). OCR of mitochondrial respiration: (OCR 
of basic state) − (OCR after the treatment with respiration inhibitors, rotenone and 
antimycin (3 μM each)). B16F10: n=3, MEF: n=3, HeLa: n=3, A549: n=5. *** p< 0.005 












Figure S2 – F2-2 and F2-3 have no obvious peaks like peak A and B in F2-1. 
(A) Fractions after SPE, F2-1, F2-2 and F2-3, were applied to a reverse-phase HPLC 
column. The results of 210- 600 nm are shown as three-dimensional chromatograms. 








Figure S3 - The area ratio of the two peaks in F2-1 and the mixed sample (emodin (EMO) 













                     
 
 
Figure S4 – Emodin-induced cellular ATP reductions in B16F10 are also evident after 24 
hours treatment at concentrations of 6 (not significant), 8, and 16 μg/mL. ** p< 0.01,  









           
              
Figure S5 – CDDP suppresses cell proliferation of B16F10 and MEF equally, but does 
not lower cellular ATP levels. 
(A) Trypan blue dye exclusion test after treatment with DMSO or CDDP (10, 30, or 100 
μM), for 24 hours. Results indicate averages and standard deviations. Statistical 
analyses were performed using total cell numbers. *** p< 0.005 (B16F10, vs. DMSO), 
††† p< 0.005 (MEF, vs. DMSO), by Dunnett’s test.  
(B) Luciferase-based ATP quantification (ToyoB-net) after treatment with DMSO or 
CDDP (10, 30, or 100 μM) for 6 hours. Results indicate averages and standard 
deviations. * p< 0.05 (vs. DMSO) by Dunnett’s test. N.S., not significant. 
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Figure S6 – MEF cells also showed stimulated respiration after addition of emodin or 












              
              
Figure S7 – The MMP of MEF cells was much lower than the MMP of B16F10 cells in 
the basic state. This figure is based on the same photos of Figure 4f, without 





            
 
Figure S8 – HeLa and A549 cells have more glycolytic reserve than B16F10 cells. 
(A) ECAR of four cell lines were analyzed by XF96 system (Seahorse).  
Rotenone + Antimycin: 3 μM each. 2-DG: 100 mM. B16F10: n=3, MEF: n=3, HeLa: 
n=3, A549: n=5. Growth media were followings; B16F10 and MEF cells: RPMI1640. 
HeLa and A549: DMEM (High glucose). For the experiments using XF96 system, we 
used XF system-specified media (Seahorse). All experiments were performed with 
10% fetal bovine serum. 
(B) HeLa and A549 cells were treated with DMSO, emodin, uncouplers (CCCP, FCCP, 
or DNP), or CDDP, for 24 hours, and cells were subjected to a trypan blue dye-
exclusion test. Results indicate averages and standard deviations of three wells. 
Statistical analyses were performed using total cell numbers. ** p< 0.01, *** p< 0.005 
(vs. DMSO), by Dunnett’s test. N.S., not significant. 
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Figure S9 - MEF cells avoid emodin-induced perturbations, such as energy depletion 
and reduced proliferation, by virtue of an intact glycolytic reserve. 
(A) Luciferase-based ATP quantification after 6 hours culture with or without emodin (8 
μg/mL), with or without glucose (200 mg/dL). Results indicate averages and standard 
deviations of three wells. ** p< 0.01, *** p< 0.005 (vs. DMSO), by Student’s t test. N.S., 
not significant. 
(B)(C) Trypan blue dye exclusion test (A) and photos (B) Photos (B) and trypan blue dye 
exclusion test (C) after culture with or without emodin (8 μg/mL), for 24 hours, with or 
without 200 mg/dL of glucose. Scale bar, 250 μm. Results indicate averages and 
standard deviations of three wells. *** p< 0.005 (vs. DMSO) by Student’s t test. N.S., 
not significant. The statistical analyses of (C) were performed using total cell numbers. 










Figure S10 – The antioxidant N-acetyl-L-cysteine (NAC) does not eliminate the anti-
proliferative effect of emodin. Scale bar, 250 μm. 
 
 
 
